BrightPath Biotherapeutics

OverviewSuggest Edit

BrightPath Biotherapeutics is a company that specializes in cancer immunotherapy. It develops a cancer peptide vaccine GRN-1201, immunomodulatory antibodies, and other products. In addition, the company focuses on induced pluripotent stem cell (iPSC)-derived regenerated natural killer T-cells (NKT) therapy.
TypePublic
Founded2003
Websitebrightpathbio.com

Latest Updates

Employees (est.) (Mar 2019)42
Share Price (Nov 2021)¥126
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at BrightPath Biotherapeutics

Akira Yamada

Akira Yamada

Director and Professor, Kurume University Research Center for Innovative Cancer Therapy
Kenichi Nagai

Kenichi Nagai

CEO
Norihiro Nakamura

Norihiro Nakamura

CSO
Show more

BrightPath Biotherapeutics Financials and Metrics

BrightPath Biotherapeutics Revenue

Market capitalization (10-Nov-2021)

6.2b

Closing stock price (10-Nov-2021)

126.0
BrightPath Biotherapeutics's current market capitalization is ¥6.2 b.
Show all financial metrics

BrightPath Biotherapeutics Online and Social Media Presence

Embed Graph

BrightPath Biotherapeutics Frequently Asked Questions

  • When was BrightPath Biotherapeutics founded?

    BrightPath Biotherapeutics was founded in 2003.

  • Who are BrightPath Biotherapeutics key executives?

    BrightPath Biotherapeutics's key executives are Akira Yamada, Kenichi Nagai and Norihiro Nakamura.

  • How many employees does BrightPath Biotherapeutics have?

    BrightPath Biotherapeutics has 42 employees.

  • Who are BrightPath Biotherapeutics competitors?

    Competitors of BrightPath Biotherapeutics include Triumvira, TYME and Luye Pharma.